Lenalidomide Pharmascience

Lenalidomide, the active ingredient in Lenalidomide Pharmascience, is an immunomodulatory antineoplastic presented as an oral formulation for systemic use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with a del(5q) chromosome abnormality, typically in adult patients.

GNH USA supplies Lenalidomide Pharmascience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy.

Multiple myeloma: improves progression‑free and overall survival in newly diagnosed and relapsed disease. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias. Maintenance after autologous stem‑cell transplant in multiple myeloma: prolongs remission duration.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Neutropenia: reduced neutrophil counts. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Rash: skin irritation or erythema. - Constipation: difficulty passing stool. - Nausea: feeling of sickness.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: heightened infection risk. - Serious infections: opportunistic or bacterial infections. - Secondary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters. - Pregnancy: contraindicated; category X, require effective contraception. - Thrombosis risk: assess history and consider prophylactic anticoagulation. - Renal function: adjust monitoring in impaired patients. - Hepatic function: monitor liver enzymes regularly. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection. - Strong CYP3A4 inducers (e.g., rifampin): may reduce drug exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): increased bleeding risk. - Antihypertensives: potential additive hypotensive effect. - Immunosuppressants (e.g., cyclosporine): heightened infection susceptibility.